Melanoma breakthrough paves way for personalised treatment for all cancer patients
14 February 2019
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
The groundbreaking research, published in Cancer Cell by a team of researchers from Melanoma Institute Australia (MIA), identifies markers of response and resistance in metastatic melanoma patients.
Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long, said the findings have the potential to revolutionalise how treatment is delivered for all cancer patients.
‘Immunotherapy is the new frontier of melanoma treatment, and whilst it has had astounding results for patients who respond, there has been a subset of patients who are resistant to the treatment,’ Professor Long said.
‘Being able to identify the immune markers of response takes out the guess work, and allows us to be proactive in providing the right drug treatment for the right patients. This has the potential to revolutionise how all cancers are treated around the world.’
The Melanoma Institute Australia team, led by PhD student Tuba Nur Gide and postdoctoral scientists Camelia Quek and James Wilmott, performed immune profiling on 158 tumour biopsies from melanoma patients treated with anti-PD-1 monotherapy or combined anti-PD-1 and anti-CTLA-4 therapy.
They found that genes involving immune memory and activation were higher in responders to immunotherapy, whereas non-responders showed higher levels of genes related to tumour adaptation and cancer cell survival.
Examining more closely the immune cells in the tumours of responders, a specific sub-type of T-cell was found to be correlated with response and survival. Patients with this immune cell had significant shrinkage of their tumours, and longer progression-free survival .
Non-responding patients were found to lie in two distinct groups – one that can possibly benefit from other available treatment combinations, and another that requires more research into novel treatment strategies. The first group were seen to have several other potential therapeutic targets, possibly leading to the development of individualised immunotherapy for selected patients.
‘In addition to knowing up front which patients are likely to respond to current immunotherapy treatments, these findings will also enable us to focus research efforts on developing new therapies targeting the biological markers identified in current non-responders,’ Professor Long added.
‘The result will be personalised immunotherapy treatment for all patients, based not on their type of cancer, but based on their tumour’s unique biology.’
The study is the largest dataset of patients treated with anti-PD-1-based therapies to be published to date, and this data is now available for use by researchers and clinicians internationally.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.